A propos Startup365

Chaque jour nous vous présenterons une nouvelle Startup française ! Notre pays regorge de talents et d'entrepreneurs brillants ! Alors partons à la découverte des meilleures startup françaises ! Certaines d'entre elles sont dans une étape essentielle dans la vie d'une startup : la recherche de financement, notamment par le financement participatif (ou crowdfunding en anglais). Alors participez à cette grande aventure en leur faisant une petite donation ! Les startups françaises ont besoin de vous !

Abora Solar l’avenir de toute votre énergie domestique sur votre toit

Cela fait des années maintenant que nous connaissons les panneaux solaires ou encore photovoltaïques. Aujourd’hui, une transition est en marche grâce à la start-up franco-espagnole Abora Solar. Si vous n’en avez jamais entendu parler, sachez que cette start-up a été fondée en 2017 dans un seul but, trouver un nouveau moyen de proposer une production électrique et thermique innovante.

De multiples récompenses et des heures d’ensoleillement plus tard, la firme est aujourd’hui capable d’alimenter de grands bâtiments en chaleur, mais aussi en eau chaude et bien évidemment en électricité.

Cela fait des années maintenant que nous connaissons les panneaux solaires ou encore photovoltaïques. Ces outils contribuent fortement à plusieurs choses : faire en sorte de réduire les émissions de gaz à effet de serre, réduire au mieux nos consommations d’énergie quotidiennes, faire en sorte d’optimiser au mieux les technologies dont nous disposons. Aujourd’hui, une transition est en marche grâce à la start-up franco-espagnole Abora Solar. Si vous n’en avez jamais entendu parler, sachez que cette start-up a été fondée en 2017 dans un seul but, trouver un nouveau moyen de proposer une production électrique et thermique innovante.

De multiples récompenses et des heures d’ensoleillement plus tard, la firme est aujourd’hui capable d’alimenter de grands bâtiments en chaleur, mais aussi en eau chaude et bien évidemment en électricité. Le tout est pensé pour être durable, propre et aussi local. En ce qui concerne le souci de fourniture d’énergie ou encore un blocus d’un autre pays fournisseur, n’y songez même pas. Cette technologie permet de prendre les devants si jamais un tel scénario venait à se réaliser.

Force est de constater, qu’en trois ans, la start-up est présente sur pas moins de 10 pays : Grèce, Colombie, Portugal, Islande, Allemagne, Suisse, Guyane, Hollande et enfin bien évidemment en Espagne et en France. Depuis le début de cette année 2020, un projet de développement commercial pour la France a été mis en place et le but de la firme est d’implanter son installation en Europe.

Actuellement, les bâtiments qui profitent de ce type d’installations sont les hôpitaux, les centres sportifs, les hôtels ou encore des universités et des écoles. Ce sont eux qui profiteront le plus de ces installations et qui surtout reviendront très vite sur leurs investissements. Espérons que d’ici quelques années, cette technologie puisse débarquer sur nos toits de particuliers.

En ce qui concerne l’installation de ce type panneaux, elle doit être réalisée par des professionnels. Comme nous vous l’avons signalé, Abora Solar propose actuellement ses services pour le secteur du B2B. Ce même secteur fait généralement appel à différentes entreprises, des sous-traitants, voire même des boîtes telles que Boels pour la location de matériel de construction ou encore roulant. Ils disposent également d’un service de location élévateur professionnel très intéressant. D’autres bureaux d’études tels que Studis Ingénierie, Optimenergi, thermikal et autres, proposeront leurs services afin d’établir le meilleur diagnostic possible pour les futurs chantiers.

Interrogée sur le sujet, Sandrine Pitel, chargée d’affaires France chez Abora Solar répond : Nos panneaux sont reconnus internationalement, ils ont reçu plusieurs prix d’excellence, dont l’Energy Globe Awards, l’EU Seal of Excellence, ou encore Solar Impulse. Récemment, nous avons reçu une importante subvention de l’UE pour notre prochain projet d’amélioration de PVT2. Nous avons été le seul projet lié à l’énergie solaire à avoir bénéficié de cette aide dans toute l’Europe.

N’hésitez pas à jeter un oeil sur le site d’Abora Solar si vous souhaitez obtenir de plus amples informations. Si vous êtes un professionnel et que ce type d’installation vous intéresse, il serait judicieux d’y songer, car tous les ingrédients sont réunis ici pour offrir une solution durable, propre, rentable et aussi idéale pour un avenir meilleur.

Comment récupérer les données sur un disque dur externe ?

Quelque soit le secteur d’activité, l’informatique et le digital ont pris une place prépondérente dans la gestion de toutes les startups (CRM, base de données clients, sauvegarde obligatoire de la comptabilité, etc.). Pour ne perdre aucune donnée importante, il est fortement conseillé de tout sauvegarder sur un disque dur externe. Ainsi, en cas de crash brutal de votre ordinateur, vous aurez une sauvegarde sécurisée. Mais… que se passe-t-il lorsque votre disque dur externe crash également ? Est-il possible de récupérer vos données ?

Soyons franc dès le début : à moins que vous soyez un expert en informatique, il n’est pas conseillé d’essayer de le réparer soit même, au risque d’aggraver les domages et d’augmenter la quantité de données perdus. Il vous faudra donc contacter au plus vite une entreprise spécialisée dans la récupération de données sur un disque dur externe. C’est un secteur de niche pour l’instant, mais il existe néanmoins plusieurs compagnies proposant ce type de services. Il vous faudra donc bien choisir et bien vous renseigner sur la qualité du service proposé par ces différentes entreprises. N’hésitez pas à demander des avis de la part d’anciens clients ou de comparer les avis disponibles sur plusieurs sites.

Le prix d’un tel service de récupération des données dépendra fortement de la taille de votre disque dur externe et de la quantité de données qui y sont récupérables. La marque et le modèle de votre disque dur externe influera peu sur le prix finale, mais plutôt la gravité et la technicité de la panne, ainsi que la quantité de données à récupérer. Néanmoins, même relativement élevé, ce prix sera rapidement compensé par la quantité d’informations récupérées et par le temps que vous allez économiser en essayant de reproduire ou recompiler toutes ces données perdues. De plus, ce type de service peut généralement être fournit assez rapidement, et certaines entreprises proposent même un « service express », moyennant un petit supplément. Bien utile si votre disque dur crash la veille ‘dune deadline imoportante !

Inutiles donc de passer des jours entiers à replonger dans vos vieux emails pour retrouver toutes les infos importantes. Ce gain de temps pharamineux (sans compter le risque d’oubli d’informations) vaudra largement le prix à payer pour récupérer ces données. Et pour éviter que cela se reproduise, il est conseillé désormais de sauvegarder toutes vos données importantes non pas sur un mais sur deux disques externes et de le garder dans 2 endroits différents (la probabilité que les deux disques durs externes crashent en même temps est quasiement nulle).

#UK Immigration rules: Covid meets Brexit

//

The UK left the EU on 31 January 2020 but since then we have been insulated from the effects thanks to the Brexit transition period. This will end on 31 December, writes Clare Hedges, Legal Director and Head of Immigration, Birketts LLP.

Free movement of people will cease and from 1 January 2021, international recruitment and business travel will look very different. Whilst we may have been distracted by COVID-19 and much has been put on hold due to the pandemic, we should still be planning for what lies ahead.

The end of free movement means that British nationals planning trips to the EU in 2021 will need to comply with the local rules of any EU country they wish to enter. 

It may be tempting to see the EU as a block, in particular those countries which are members of the Schengen area, but individual State competence is expressly reserved for immigration matters, which means each country makes its own rules. 

Whilst the EU is encouraging all of its members to facilitate visa-free entry by British nationals for the purposes of tourism, this does not apply to work trips. 

If you are planning business travel in 2021, you should consult immigration lawyers in your destination country who can advise on local requirements. In the meantime, there is some basic information available online: https://www.gov.uk/government/collections/providing-services-to-eea-and-efta-countries-after-eu-exit

Of course the change also means that EU nationals will become subject to UK immigration rules. 

EU nationals will not require advance entry clearance if they are simply visiting the UK. They can apply for entry at the border. 

They will be able to use automatic e-gates, instead of showing their passport to an entry clearance officer. This means they will not obtain a stamp. It is therefore imperative that travellers keep their own record of their trips, to ensure they comply with the rule that you can only visit the UK for up to 180 days in any 12-month period. 

Employers will also have a vested interest in keeping careful records. Even if an individual is working and paid abroad, overseas business visitors still need to be reported to HMRC.

The current immigration rules (which will be updated soon) allow a range of activities for business visitors. These include attending meetings, conferences and interviews, but business visitors cannot work in the UK. 

You do need to be careful as any allegation of illegal working carries stiff penalties for the employer and the individual and can also prejudice the employer’s Home Office sponsor licence. 

The Home Office will be well aware of potential for EU national business visitors to abuse and break the rules and so we do anticipate an increase in audits and enforcement.

If you need to employ an EU national in the UK in 2021, it is likely that you will require a sponsor licence. Current Tier 2 licenses are being transferred across into the new Points Based Immigration system, but if you do not already have one, you should apply now.

You should also encourage any EU or EEA nationals in your organisation, who are based in the UK, to apply now for settled or pre-settled status under the EU Settlement Scheme. 

There is a grace period to apply until 30 June 2021, but anybody who is eligible to apply should do so as soon as possible. 

It is a straightforward process, completed using a smartphone app. There is normally no need to attend an appointment or send away documents and therefore the process can be completed in a covid-secure manner at home.

The pandemic has led to many employees working remotely, in some cases from abroad. EU nationals who have been spending time outside the UK need to consider what effect this will have on their ability to obtain and retain pre-settled and settled status. 

Whilst many may be tempted to avoid a covid-filled UK winter, they might just discover this is the perfect time to return!

• Feel free to call Clare Hedges on 01223 326 605 or email clare-hedges [at] birketts.co.uk

from Business Weekly https://ift.tt/3f13i2i

Publié dans #UK

#UK AstraZeneca and GSK back new Cambridge centre for AI in medicine

//

Jim Weatherall of AstraZeneca

A gamechanging alliance of machine learning and bioscience with massive global implications for human health has been launched in Cambridge.

The University of Cambridge has unveiled a five-year agreement with AstraZeneca and GSK to fund the Cambridge Centre for AI in Medicine (CCAIM). 

For the five-year duration, AstraZeneca and GSK will support five new PhD studentships per year. This program will enable the best and brightest young minds in machine learning and bioscience to partner with leaders in industry and academia, wherever they may be in the world.

CCAIM has been set up as a cutting-edge research group. Its faculty of 10 University of Cambridge researchers – in addition to world-class PhD students, currently being recruited – have united to develop AI and machine learning technologies aiming to transform clinical trials, personalised medicine and biomedical discovery.

The centre’s director is Professor Mihaela van der Schaar, a world leading researcher in machine learning and the co-director is researcher-clinician Professor Andres Floto. 

The faculty also includes Dr Sarah Teichmann – head of cellular genetics at the Wellcome Sanger Institute and founder and principal leader of the Human Cell Atlas international consortium.

Bridging the gap between the disparate and complex fields of AI and medicine requires building from both sides simultaneously. CCAIM brings together a diverse coalition of leading Cambridge scientists and clinicians, with expertise in machine learning, engineering, mathematics, medicine, computer science, genetics, computational biology, biostatistics, clinical research, healthcare policy and more.

These multi-disciplinary experts from the University of Cambridge will work in close collaboration with scientists and leaders from AstraZeneca and GSK to identify  critical challenges facing drug discovery and development that have the potential to be solved through cutting-edge academic research.

The centre’s research output and the implementation of its ML tools could be transformational not only for the pharmaceutical industry – including in clinical trials and drug discovery – but also for the clinical delivery of healthcare to patients. The CCAIM team already has deep research links with the NHS, and four of the centre’s members are NHS doctors.

Professor Andy Neely, Pro-Vice-Chancellor for Enterprise and Business Relations, University of Cambridge, said: “The Cambridge Centre for AI in Medicine is a terrific and timely venture that builds on the strong relationships between the University of Cambridge and global leaders in the pharmaceutical industry, AstraZeneca and GSK.

“The depth and diversity of the CCAIM faculty’s expertise means it is uniquely positioned to deliver and accelerate the breakthroughs in medical science and healthcare that AI has long promised. I anticipate the centre’s impact will be nothing less than transformational.”

Jim Weatherall, VP of data science & AI, R & D, AstraZeneca, added: “We know the best science doesn’t happen in isolation which is why collaboration is essential to the way we work.

“This new centre combines world class academia with real-world industrial challenges and will help to develop cutting-edge AI to potentially transform the way we discover and develop medicines.”

from Business Weekly https://ift.tt/3kmyHx1

Publié dans #UK

#UK Cambridge Wireless and Huawei build first private 5G testbed at Science Park

//

CW (Cambridge Wireless), an international community for companies involved in the research, development and application of wireless technologies, is teaming up with global technology leader Huawei to deploy and build Cambridge’s first 5G mobile private network within the Science Park. 

The new set-up will allow Cambridge’s world-renowned technology community to undertake cutting edge new digital research and application in key areas such as autonomous vehicles, clean energy and remote surgery. 

The 5G testbed will go live in January and kicks off a three-year partnership between Cambridge Wireless and Huawei, which will involve digital training, business support and joint events. 

The aim is to explore how advanced wireless technology can have a far-reaching impact on both society and the economy. 

“We are constantly working to provide value to CW members,” said Simon Mead, CEO of CW. 

“As home to one of the world’s most advanced R & D ecosystems, Cambridge is perfectly positioned for the rollout of next generation wireless technology and we’re delighted to be driving this initiative with our partners.
 
“We hope to bring something unique to the Science Park to accelerate use cases and development of this technology. We invite ambitious businesses to get involved and through this exciting three-year partnership with Huawei we will support their 5G innovation journey.” 

Huawei vice-president Victor Zhang described the partnership as a key part of the business’s ongoing commitment to the UK. 

He said: “Huawei’s success is built on a relentless drive for innovation and we are able to keep pushing the boundaries of technology when we partner with those who share this ambition. 

“The Cambridge eco-system is recognised as a global leader in technology and we are excited to work with the talent and vision in this eco-system. We hope to enable Cambridge Wireless members to reach new heights by allowing them access to our state-of-the-art equipment and markets including China and beyond. 

“Our commitment to the UK and industry remains as strong as ever and we will continue to offer our expertise and technology to our partners to promote connections and innovation.”

The 5G testbed will be based at Cambridge Science Park, owned by Cambridge University, which is currently home to more than 120 tech companies and scale-ups.

Additional partnerships with TusPark UK and Freshwave have been developed to accelerate the digitalisation of The Cambridge Science Park and enable businesses to exploit new capabilities, boost innovation and gain competitive advantage as they shift towards the adoption of 5G.

“We are looking for organisations who would like to create, accelerate and test out new and innovative applications and products on the CW 5G Testbed,” said Abhi Naha, chief commercial officer at CW.

• The 5G Testbed will be launched in January 2021. To find out more and how to get involved, call Abhi Naha on +44(0)1223 967 101 or email him at: abhi.naha [at] cambridgewireless.co.uk

from Business Weekly https://ift.tt/3ks7J7q

Publié dans #UK

#Asia #Japan Why startups should be better than charities at solving social problems

//

Startups exist to develop new solutions to problems.

But many of society’s biggest problems fall outside traditional startup business models.

Today we explore why that is, and how it might be changed as we sit down with Robin Lewis, co-founder of Mymizu, a startup focused on reducing plastic waste by encouraging reuse.

We take a deep dive into possible monetization strategies, why startups should be better at solving social problems than non-profits, and we discuss a possible roadmap for a middle path between startups and non-profits.

It’s a great conversation, and I think you’ll enjoy it.

Show Notes

The Japanese middle-ground between NGOs and for-profit startups
The hidden strategy behind beach cleanup programs
Mymizu’s current business model
The challenge of mixing environmental and social sustainability
When Tim became “The Destroyer of Dreams”
The unexpected (positive ) impacts of COVID-19
Why startups  should be able to do more social good than NGOs
How bottled water breaks economic theory
What happened to Japanese water fountains
One common recycling scam in Japan
A roadmap for the middle path between NGO and startup

 

Links from the Founder

Everything you ever wanted to know about Mymizu
Follow Mymizu on Instagram
Check out Robin’s personal home page
Follow his blog on social sustainability
Follow him on Twitter @robintlewis
Connect with him on LinkedIn
More about sustainability in Japan

7 Surprising Facts About Plastic in Japan
Sanpo Yoshi: the Japanese business principle of success through responsibility
25 Opportunities For Volunteering and Social Good in Japan

Milton Friedman’s landmark NYT article on corporate responsibility

Leave a comment
Transcript
Welcome to Disrupting Japan, straight talk from Japan’s most successful entrepreneurs.
I’m Tim Romero and thanks for joining me.
Water, it’s one of the most common molecules in the universe and you personally are made up of about 60% water. There are a number of significant problems today that revolve around water but water is rarely the focus for startups, and today, we’re going to explore why that is and why that might be changing.
Today, we sit down in a properly socially distanced matter and talk with Robin Lewis, co-founder of Mymizu. The Mymizu app enables you to find places to refill your water bottles all over Japan, and the company itself exists in a very interesting space between nonprofit and a regular for profit company.
Robin and his team are already making an impact in Japan, and we have a deep dive into how startups can be a force to achieve meaningful social change. The challenges of balancing the need for revenues with staying true to your social mission, and we brainstorm about possible monetization strategies that could enable that, and also, you’ll learn something that will probably really piss you off about how recycling is done in Japan.
But you know, Robin tells that story much better than I can, so let’s get right to the interview.

Interview
Tim: So I’m sitting here with Robin Lewis, the co-founder of Mymizu, a water refilling app. Thanks for sitting down with me.
Robin Lewis: Thanks so much for having me, Tim, I’m excited to be here.
Tim: Actually, you can explain Mymizu much better than I can, so what is Mymizu exactly?
Robin: Mymizu, what we’re doing is we’re on a mission to help people live more sustainably, starting with plastic bottles. We accomplish that in, I’d say, four main ways. First, we have the app which you mentioned and it’s essentially a tool where you can find 200,000 locations around the world where you can take your reusable bottle and refill that for free, and so this includes public water fountains like in train station, in parks, and so on, but also, we have this network of what we call ‘refill partners,’ this is cafes, shops, hotels, and other businesses where you can walk in, you can get your water,

from Disrupting Japan: Startups and Innovation in Japan https://ift.tt/36kViF7

#UK Congenica raises $50m growth capital through Asian, Gulf and UK investors

//

David Atkins Congenica

Cambridge genomic data pioneer Congenica has raised a stunning $50 million Series C funding from one of the most international syndicates ever assembled for a UK deal.

UK blue chip business Legal & General is partnered by players from China, Malaysia and Oman in backing the digital health trailblazer, which was spun out of the Sanger Institute. It is based at the Wellcome Genome Campus.

Congenica is using the cash to advance both its clinical genomic analysis software and its data platform. Executives say this will drive further commercialisation of rare and inherited cancer applications and expansion into oncology, wellness and pharmaceutical collaborations.

The company’s technology already enables rapid and accurate analysis of complex genomic data to transform people’s lives.

The blockbusting Series C was co-led by Tencent (China) and Legal & General (UK) and included other new investors Xeraya (Malaysia), Puhua Capital (China) and IDO Investments (Oman). Existing investors Parkwalk, Cambridge Innovation Capital and Downing also participated. Lazard acted as sole financial adviser to the company.

The international nature of this important financing round brings new strategic and geographic capabilities that will further advance Congenica’s existing global footprint.

A pioneer in genomic analysis, Congenica has established a diverse, global customer-base of hospitals, diagnostic laboratories, academic medical centres and pharmaceutical companies based on its exceptional scientific heritage from the Wellcome Sanger Institute and as the exclusive Clinical Decision Support service provider in the delivery of the ground-breaking UK NHS Genomic Medicine Service. Congenica’s initial commercial success has led to a customer network spanning 18 countries.

Congenica will deliver advanced capabilities including the ability to integrate with existing electronic health systems and deliver fully automated interpretation capability. Underpinning Congenica’s value is its unparalleled use of a vast range of high quality data sources.

By integrating its software into existing systems and infrastructure, and further developing ground-breaking machine learning capabilities, Congenica is building a future where personalised decisions and treatments, guided by genomic information, can be routinely used to transform the health and wellness of individuals around the world.

Congenica CEO Dr David Atkins, said: “Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. 

“This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets.”

Congenica’s world-leading software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30 per cent higher analytical yield, reducing genomic interpretation costs by up to 95 per cent.

Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies.

from Business Weekly https://ift.tt/3n7uX4o

Publié dans #UK

L’Intelligence Artificielle et le Machine Learning s’invitent dans le secteur des Paris Sportifs

Le boom technologique de l’Intelligence Artificielle et du Machine Learning a atteint de nombreux secteurs (médecine, software, etc.) et ouvre de nouveaux horizons dans des secteurs jusque là réfractaires à l’innovation. Un des exemples les plus parlant est le secteur des Paris Sportifs.

Dans un secteur plus connus pour ses fraudes et ses matchs truqués que pour son côté innovant (relayés par exemple par des sites web comme Betmaker), les nouvelles technologies font leurs apparitions dans un secteur qui en a cruellement besoin. Venu principalement d’Asie et de ses gros Bookmakers, l’entrée de l’Intelligence Artificielle et du Machine Learning dans les paris sportifs permet aux parieurs une analyse beaucoup plus poussés et en temps réel des probabilités de victoires, en tenant compte d’une infinité de paramètres des parties précédentes de ces deux équipes (effets des changements de joueurs, des cartons ou pénalités reçus, des tactiques mises en places, des choix préférentielles des entraineurs, de la metéo, etc.).

Dans un secteur où les donnés (les fameuses « data ») ont de plus en plus d’importance, aussi bien dans la préparation physique que dans la préparation tactique des matchs, l’analyse et la structuration de ce flot continue de données par l’Intelligence Artificielle et le Machine Learning permet une vision beaucoup plus précise et en temps réel des probabilités de victoires, mais également des performances individuelles de chaque joueur (probabilité de marquer, de blessures, de cartons/pénalités).

Cela ouvre de grandes opportunités pour des entrepreneurs audacieux qui maîtrisent les rouages de ces technologies de pointes (AI et ML), dans un secteur risqué (car fortement régulé et surveillé) mais terriblement attractif de par sa taille et le statu-quo qui y règne depuis bien trop longtemps.

#UK US swallows another Cambridge gem as Horizon sells to PerkinElmer for $383m

//

Horizon Discovery laboratory

The relentless march of Cambridge science & technology companies into US hands continued today as Horizon Discovery, a world gene editing leader, revealed it was being acquired by Wall Street quoted PerkinElmer for $383 million.

In recent weeks NVIDIA has swallowed Arm for $40 billion, DisplayLink was sold to Synaptics, which is already plotting major redundancies in Cambridge, and F-star reversed into a NASDAQ IPO.

The swoop by Massachusetts  based PerkinElmer for Horizon is an all-cash offer and is expected to close in the first quarter of 2021.

It is all upside for PerkinElmer which says it will expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools. 

The acquisition will enable PerkinElmer to better partner with academic and pharma/biopharma scientists to help meet research challenges. It will also provide an opportunity to provide important tools for exploring next generation cell engineering and customised cell lines for relevant biological models – important for the future of precision medicine.

Horizon has been a sitting duck since incredibly deciding to part company with inspirational CEO Darrin Disley. The company is a leading provider of CRISPR and RNAi reagents, cell models, cell engineering and base editing offerings which help scientists better understand gene function, genetic disease drivers and biotherapeutics delivery. 

Horizon has approximately 400 employees across multiple countries, including the UK, the US and Japan and reported revenue from continuing operations of $75.5 million in 2019.

PerkinElmer’s discovery and applied genomics solutions feature a range of immunoassay platforms, high content screening (HCS) and in vivo imaging, along with microfluidics, robotic liquid handling technologies and next-generation sequencing library preparation kits.

Unifying PerkinElmer’s and Horizon’s complementary offerings across the genotypic and phenotypic approaches for drug discovery and development will help researchers accelerate decision making with better information, automated workflows and greater quality and control over data.

Prahlad Singh, president and CEO at PerkinElmer said: “One of the key fundamentals for molecular research and drug discovery is being able to knock down a gene or function and explore the results to discover actionable insights and new clinical trial candidates faster. 

“We’re excited to team up with Horizon not only to add CRISPR and RNAi capabilities into our existing portfolio but also to leverage our combined life sciences screening and applied genomics solutions to help propel the next phase of cell and gene research for precision medicine. 

“PerkinElmer leads with science and creates total solutions to bring today’s leading innovations together for our customers, while also working at the cutting edge of what’s next. Today’s announcement delivers on both of these fronts.”

from Business Weekly https://ift.tt/3jNeEHN

Publié dans #UK